Sep

18

2021

What is the mechanism of action of Crizanlizumab in reducing pain crises in sickle cell disease (SCD)?

By William Aird

A

What is the mechanism of action of Crizanlizumab in reducing pain crises in sickle cell disease (SCD)?

Crizanlizumab is a monoclonal antibody medication that binds to P-selectin, inhibiting white blood cell-endothelial and platelet-endothelial interactions on the blood vessel wall.

Stay Updated

If you are interested in getting the latest articles from The Blood Project, enter your name and email

  • This field is for validation purposes and should be left unchanged.